March 2025 Publications
- Microneedle-mediated intradermal delivery of Bacille Calmette-Guérin (BCG) vaccines for single-dose tuberculosis vaccination. Lee S, Kim T, Seong KY, Yim SG, Lee WK, Kim S, Lee KO, Yang SY, Ryoo S. Tuberculosis (Edinb). 2025 Mar;151:102608. doi: 10.1016/j.tube.2025.102608. Epub 2025 Jan 16.
- An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4+ T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis. Lukeman H, Al-Wassiti H, Fabb SA, Lim L, Wang T, Britton WJ, Steain M, Pouton CW, Triccas JA, Counoupas C. EBioMedicine. 2025 Mar;113:105599. doi: 10.1016/j.ebiom.2025.105599. Epub 2025 Feb 15.
- Microneedle-mediated intradermal delivery of Bacille Calmette-Guérin (BCG) vaccines for single-dose tuberculosis vaccination. Lee S, Kim T, Seong KY, Yim SG, Lee WK, Kim S, Lee KO, Yang SY, Ryoo S. Tuberculosis (Edinb). 2025 Mar;151:102608. doi: 10.1016/j.tube.2025.102608. Epub 2025 Jan 16.
- Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices. Tengattini S, Bavaro T, Rinaldi F, Temporini C, Pollegioni L, Terreni M, Piubelli L. Vaccine. 2025 Mar 2;53:126932. doi: 10.1016/j.vaccine.2025.126932. Epub ahead of print.
- From adhesion to invasion: the multifaceted roles of Mycobacterium tuberculosis lipoproteins. Li M, Zhang Q, Wang Y, Xie J, Liang T, Liu Z, Xiang X, Zhou Q, Gong Z. J Drug Target. 2025 Mar 3:1-10. doi: 10.1080/1061186X.2025.2472208. Epub ahead of print.
- Bacille Calmette-Guérin-specific IgG titres among infants born to mothers with active tuberculosis disease in Uganda. Sitenda D, Ssekamatte P, Nakavuma R, Kyazze AP, Bongomin F, Baluku JB, Nabatanzi R, Kibirige D, Wilkinson RJ, Nakimuli A, Cose S, Andia-Biraro I. BMC Immunol. 2025 Mar 4;26(1):13. doi: 10.1186/s12865-025-00692-w.
- Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. Borges ÁH, Russell M, Tait D, Scriba TJ, Nemes E, Skallerup P, van Brakel E, Cabibbe AM, Cirillo DM, Leuvennink-Steyn M, Rutkowski KT, Wood GK, Thierry-Carstensen B, Tingskov PN, Meldgaard EC, Kristiansen MP, Søndergaard RE, Hansen CH, Follmann F, Jensen CG, Gela A, Ntinginya NE, Ruhwald M, Shenje J, White L, Innes C, Selepe P, Ngaraguza B, Holmgren C, Collings T, Andersen P, Dawson R, Churchyard G, Sabi I, Diacon AH, Mortensen R, Hatherill M; POR TB study group. Lancet Infect Dis. 2025 Mar 5:S1473-3099(24)00814-4. doi: 10.1016/S1473-3099(24)00814-4. Epub ahead of print.
- Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on the phase 2b trial results. Dale KD, Denholm JT. Vaccine. 2025 Mar 7;49:126816. doi: 10.1016/j.vaccine.2025.126816. Epub 2025 Jan 31.
- Scale-up of a low-temperature spray-drying process for a tuberculosis vaccine candidate using lab-scale equipment. Aisenstat M, McCollum J, Ordoubadi M, Wang H, Minootan Z, Gerhardt A, Martin AR, Fox CB, Vehring R. Int J Pharm. 2025 Mar 10;674:125456. doi: 10.1016/j.ijpharm.2025.125456. Epub ahead of print.
- BCG-derived acellular membrane vesicles elicit antimycobacterial immunity and innate immune memory. Yamaguchi T, Samukawa N, Matsumoto S, Shiota M, Matsumoto M, Nakao R, Hirayama S, Yoshida Y, Nishiyama A, Ozeki Y, Tomita S. Front Immunol. 2025 Mar 12;16:1534615. doi: 10.3389/fimmu.2025.1534615.
- Bioinformatics analysis, immunogenicity, and therapeutic efficacy evaluation of a novel multi-stage, multi-epitope DNA vaccine for tuberculosis. Guo J, Jia Z, Yang Y, Wang N, Xue Y, Xiao L, Wang F, Wang L, Wang X, Liu Y, Wang J, Gong W, Zhao H, Liang Y, Wu X. Int Immunopharmacol. 2025 Mar 13;152:114415. doi: 10.1016/j.intimp.2025.114415. Epub ahead of print.
- Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting. Tameris M, Rozot V, Imbratta C, Geldenhuys H, Mendelsohn SC, Kany Luabeya AK, Shenje J, Tredoux N, Fisher M, Mulenga H, Bilek N, Young C, Veldsman A, Botes N, Thole J, Fritzell B, Mukherjee R, Jelsbak IM, Rodriguez E, Puentes E, Doce J, Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C, Scriba TJ, Hatherill M; MTBVAC 202 study team. EBioMedicine. 2025 Mar 17;114:105628. doi: 10.1016/j.ebiom.2025.105628. Epub ahead of print.
- Sensing mycobacteria through unconventional pathways. Almeida CF, Juno JA. J Clin Invest. 2025 Mar 17;135(6):e190230. doi: 10.1172/JCI190230.
- Timing matters in macrophage/CD4+ T cell interactions: an agent-based model comparing Mycobacterium tuberculosis host-pathogen interactions between latently infected and naïve individuals. Hoerter A, Petrucciani A, Bonifacio J, Arnett E, Schlesinger LS, Pienaar E. mSystems. 2025 Mar 18;10(3):e0129024. doi: 10.1128/msystems.01290-24. Epub 2025 Feb 7.
- Deconvoluting the interplay of innate and adaptive immunity in BCG-induced nonspecific and TB-specific host resistance. Hilligan KL, Darrah PA, Seder RA, Sher A. J Exp Med. 2025 Mar 18. doi: 10.1084/jem.20240496. Epub ahead of print.
- Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuberculosis Vaccine Formulation (ID93 + GLA-LSQ). Adeagbo BA, Alao M, Orherhe O, Akinloye A, Boukes G, Willenburg E, Fenner C, Bolaji OO, Fox CB. Mol Pharm. 2025 Mar 19. doi: 10.1021/acs.molpharmaceut.5c00150. Epub ahead of print.
- Trained immunity-based mucosal immunotherapies for the prevention of respiratory infections. Minute L, Montalbán-Hernández K, Bravo-Robles L, Conejero L, Iborra S, Del Fresno C. Trends Immunol. 2025 Mar 19:S1471-4906(25)00055-9. doi: 10.1016/j.it.2025.02.012. Epub ahead of print.
- The development of a subunit vaccine for Mycobacterium tuberculosis Rv0081 as a booster for BCG and the investigation of its immunogenicity. Xu Y, Zhong Q, Wang X, Liu X, Zhang Z, Kong L, Zhou M, Wang R. J Microbiol Methods. 2025 Mar 26:107121. doi: 10.1016/j.mimet.2025.107121. Epub ahead of print.
- Prediction of a novel synthetic peptide vaccine against tuberculosis and validation of its immunogenicity. Zhang D, Wang D, Jiang S, Wan Y, Zhao Y, Dong W, Li X, Fu L, Zhang W. Int Immunopharmacol. 2025 Mar 27;153:114531. doi: 10.1016/j.intimp.2025.114531. Epub ahead of print.
- M. Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine. Felgueres MJ, Esteso G, García-Jiménez ÁF, Benguría A, Vázquez E, Aguiló N, Puentes E, Dopazo A, Murillo I, Martín C, Rodríguez E, Reyburn HT, Valés-Gómez. NPJ Vaccines. 2025 Mar 28;10(1):58. doi: 10.1038/s41541-025-01110-3.